{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:07:25Z","timestamp":1792501645932,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01380-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:52:29Z","timestamp":1768805549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches"],"prefix":"10.1007","volume":"27","author":[{"given":"Justin M.","family":"Hintze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Chintakuntlawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41199-016-0011-z","volume":"1","author":"AV Chintakuntlawar","year":"2016","unstructured":"Chintakuntlawar AV, Okuno SH, Price KA. Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck. 2016;1:11.","journal-title":"Cancers Head Neck"},{"issue":"4","key":"1380_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jjco\/hyac008","volume":"52","author":"Y Imamura","year":"2022","unstructured":"Imamura Y, Kiyota N, Tahara M. Systemic therapy for salivary gland malignancy: current status and future perspectives. Jpn J Clin Oncol. 2022;52(4):293\u2013302.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1380_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12070-023-04104-6","volume":"76","author":"K Bhushan","year":"2024","unstructured":"Bhushan K, Sharma ML, Gupta DK. Chemotherapy for salivary gland malignant carcinoma: meta-analysis and systemic review. Indian J Otolaryngol Head Neck Surg. 2024;76(1):123\u20139.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"2","key":"1380_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","volume":"23","author":"AD Colevas","year":"2025","unstructured":"Colevas AD, Cmelak AJ, Pfister DG, et al. NCCN guidelines\u00ae insights: head and neck Cancers, version 2.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2025;23(2):2\u201311.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1380_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-022-01043-2","volume":"24","author":"AJ Kacew","year":"2023","unstructured":"Kacew AJ, Hanna GJ. Systemic and targeted therapies in adenoid cystic carcinoma. Curr Treat Options Oncol. 2023;24(1):45\u201360.","journal-title":"Curr Treat Options Oncol"},{"key":"1380_CR6","doi-asserted-by":"publisher","first-page":"103886","DOI":"10.1016\/j.critrevonc.2022.103886","volume":"181","author":"VP Wagner","year":"2023","unstructured":"Wagner VP, Ferrarotto R, Vargas PA, Martins MD, Bingle CD, Bingle L. Drug-based therapy for advanced adenoid cystic carcinoma: current landscape and challenges based on an overview of registered clinical trials. Crit Rev Oncol Hematol. 2023;181:103886.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1380_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hed.24933","volume":"40","author":"MH Hong","year":"2018","unstructured":"Hong MH, Kim CG, Koh YW, et al. Efficacy and safety of Vinorelbine plus cisplatin chemotherapy for patients with recurrent and\/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40(1):55\u201362.","journal-title":"Head Neck"},{"issue":"11","key":"1380_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01581-z","volume":"38","author":"Y Imamura","year":"2021","unstructured":"Imamura Y, Tanaka K, Kiyota N. Docetaxel plus cisplatin in recurrent and\/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial. Med Oncol. 2021;38(11):128.","journal-title":"Med Oncol"},{"issue":"3","key":"1380_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4143\/crt.2021.1019","volume":"54","author":"HR Kim","year":"2022","unstructured":"Kim HR, Lee SJ, Park S, et al. A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer. Cancer Res Treat. 2022;54(3):719\u201327.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"1380_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/COC.0000000000000112","volume":"40","author":"M Airoldi","year":"2017","unstructured":"Airoldi M, Garzaro M, Pedani F, et al. Cisplatin\u2009+\u2009Vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): A final report on 60 cases. Am J Clin Oncol. 2017;40(1):86\u201390.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"1380_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","volume":"49","author":"N Ghosal","year":"2011","unstructured":"Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and Imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg. 2011;49(7):510\u20135.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"3","key":"1380_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hed.25020","volume":"40","author":"CP Rodriguez","year":"2018","unstructured":"Rodriguez CP, Martins RG, Baik C, et al. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head Neck. 2018;40(3):584\u20139.","journal-title":"Head Neck"},{"issue":"15","key":"1380_CR13","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/cncr.29401","volume":"121","author":"B Keam","year":"2015","unstructured":"Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121(15):2612\u20137.","journal-title":"Cancer"},{"issue":"11","key":"1380_CR14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.30537","volume":"123","author":"Y Kim","year":"2017","unstructured":"Kim Y, Lee SJ, Lee JY, et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean cancer study group HN14-01). Cancer. 2017;123(11):1958\u201364.","journal-title":"Cancer"},{"issue":"18","key":"1380_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with Progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529\u201337.","journal-title":"J Clin Oncol"},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","volume":"69","author":"LD Locati","year":"2016","unstructured":"Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of Sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158\u201365.","journal-title":"Eur J Cancer"},{"key":"1380_CR17","doi-asserted-by":"publisher","first-page":"105366","DOI":"10.1016\/j.oraloncology.2021.105366","volume":"119","author":"GJ Hanna","year":"2021","unstructured":"Hanna GJ, A ON, Cutler JM, et al. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021;119:105366.","journal-title":"Oral Oncol"},{"issue":"2","key":"1380_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","volume":"38","author":"C Even","year":"2020","unstructured":"Even C, Lassen U, Merchan J, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs. 2020;38(2):402\u20139.","journal-title":"Invest New Drugs"},{"issue":"17","key":"1380_CR19","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, Guenette JP, Chau NG, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020;126(17):3972\u201381.","journal-title":"Cancer"},{"key":"1380_CR20","doi-asserted-by":"publisher","first-page":"106634","DOI":"10.1016\/j.oraloncology.2023.106634","volume":"149","author":"R Ferrarotto","year":"2024","unstructured":"Ferrarotto R, Swiecicki PL, Zandberg DP, et al. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study. Oral Oncol. 2024;149:106634.","journal-title":"Oral Oncol"},{"issue":"23","key":"1380_CR21","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-24-1064","volume":"30","author":"A Desilets","year":"2024","unstructured":"Desilets A, Vos JL, Katabi N, et al. Phase 2 trial of regorafenib in recurrent\/metastatic adenoid cystic carcinoma. Clin Cancer Res. 2024;30(23):5281\u201392.","journal-title":"Clin Cancer Res"},{"key":"1380_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","volume":"161","author":"W van Boxtel","year":"2022","unstructured":"van Boxtel W, Uijen MJM, Krens SD, et al. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer. Eur J Cancer. 2022;161:128\u201337.","journal-title":"Eur J Cancer"},{"issue":"22","key":"1380_CR23","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1158\/1078-0432.CCR-23-1030","volume":"29","author":"GJ Hanna","year":"2023","unstructured":"Hanna GJ, Ahn MJ, Muzaffar J, et al. A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2023;29(22):4555\u201363.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1380_CR24","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","volume":"23","author":"PM Dillon","year":"2017","unstructured":"Dillon PM, Petroni GR, Horton BJ, et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23(15):4138\u201345.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1380_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/annonc\/mdv537","volume":"27","author":"SJ Wong","year":"2016","unstructured":"Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27(2):318\u201323.","journal-title":"Ann Oncol"},{"issue":"10","key":"1380_CR26","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/hed.25891","volume":"41","author":"LD Locati","year":"2019","unstructured":"Locati LD, Cavalieri S, Bergamini C, et al. Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck. 2019;41(10):3670\u20136.","journal-title":"Head Neck"},{"issue":"5","key":"1380_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cncr.35103","volume":"130","author":"AL Ho","year":"2024","unstructured":"Ho AL, Foster NR, Deraje Vasudeva S, et al. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104). Cancer. 2024;130(5):702\u201312.","journal-title":"Cancer"},{"issue":"9","key":"1380_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/cncr.32754","volume":"126","author":"LD Locati","year":"2020","unstructured":"Locati LD, Galbiati D, Calareso G, et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer. 2020;126(9):1888\u201394.","journal-title":"Cancer"},{"issue":"19","key":"1380_CR29","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","volume":"27","author":"EJ Kang","year":"2021","unstructured":"Kang EJ, Ahn MJ, Ock CY, et al. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2021;27(19):5272\u20139.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1380_CR30","doi-asserted-by":"publisher","first-page":"32918","DOI":"10.18632\/oncotarget.16464","volume":"8","author":"PH Goncalves","year":"2017","unstructured":"Goncalves PH, Heilbrun LK, Barrett MT, et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget. 2017;8(20):32918\u201329.","journal-title":"Oncotarget"},{"issue":"36","key":"1380_CR31","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1200\/JCO.21.00468","volume":"39","author":"LD Locati","year":"2021","unstructured":"Locati LD, Cavalieri S, Bergamini C, et al. Abiraterone acetate in patients with Castration-Resistant, androgen Receptor-Expressing salivary gland cancer: A phase II trial. J Clin Oncol. 2021;39(36):4061\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1380_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-Positive salivary duct carcinoma. J Clin Oncol. 2019;37(2):125\u201334.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1380_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979\u201384.","journal-title":"Ann Oncol"},{"issue":"16","key":"1380_CR34","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","volume":"30","author":"Y Honma","year":"2024","unstructured":"Honma Y, Monden N, Yamazaki K, et al. Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: a phase II nonrandomized clinical trial, YATAGARASU. Clin Cancer Res. 2024;30(16):3416\u201327.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1380_CR35","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1002\/cncr.34892","volume":"129","author":"J Lee","year":"2023","unstructured":"Lee J, Park S, Jung HA, et al. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer. 2023;129(19):2966\u201374.","journal-title":"Cancer"},{"issue":"36","key":"1380_CR36","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/JCO.22.00229","volume":"40","author":"AL Ho","year":"2022","unstructured":"Ho AL, Foster NR, Zoroufy AJ, et al. Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404). J Clin Oncol. 2022;40(36):4240\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1380_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","volume":"31","author":"R Kurzrock","year":"2020","unstructured":"Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31(3):412\u201321.","journal-title":"Ann Oncol"},{"issue":"11","key":"1380_CR38","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","volume":"30","author":"KL Jhaveri","year":"2019","unstructured":"Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30(11):1821\u201330.","journal-title":"Ann Oncol"},{"key":"1380_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","volume":"171","author":"C Even","year":"2022","unstructured":"Even C, Delord JP, Price KA, et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer. 2022;171:259\u201368.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1380_CR40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez CP, Wu QV, Voutsinas J, et al. A phase II trial of pembrolizumab and Vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26(4):837\u201345.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1380_CR41","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","volume":"29","author":"JL Vos","year":"2023","unstructured":"Vos JL, Burman B, Jain S, et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med. 2023;29(12):3077\u201389.","journal-title":"Nat Med"},{"issue":"15","key":"1380_CR42","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.22.02221","volume":"41","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, Sousa LG, Feng L, et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma. J Clin Oncol. 2023;41(15):2843\u201351.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1380_CR43","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39(17):1909\u201341.","journal-title":"J Clin Oncol"},{"key":"1380_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040992","author":"LE Miller","year":"2022","unstructured":"Miller LE, Au V, Mokhtari TE, Goss D, Faden DL, Varvares MA. A contemporary review of molecular therapeutic targets for adenoid cystic carcinoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14040992.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1380_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"1380_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jjco\/hyad181","volume":"54","author":"S Takahashi","year":"2024","unstructured":"Takahashi S, Bando H, Kinoshita I, et al. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Jpn J Clin Oncol. 2024;54(4):434\u201343.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1380_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"key":"1380_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106612","volume":"148","author":"DM Filippini","year":"2024","unstructured":"Filippini DM, Pagani R, Tober N, et al. HER2-targeted therapies for salivary gland cancers. Oral Oncol. 2024;148:106612.","journal-title":"Oral Oncol"},{"issue":"10","key":"1380_CR49","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho AS, Ochoa A, Jayakumaran G, et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129(10):4276\u201389.","journal-title":"J Clin Invest"},{"key":"1380_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162868","author":"S Powell","year":"2024","unstructured":"Powell S, Kulakova K, Hanratty K, et al. Molecular analysis of salivary and lacrimal adenoid cystic carcinoma. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16162868.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1380_CR51","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Mitani Y, McGrail DJ, et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res. 2021;27(3):852\u201364.","journal-title":"Clin Cancer Res"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01380-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:02:32Z","timestamp":1768849352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01380-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01380-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required as this study was based on previously published data. However, all included studies adhered to ethical guidelines set by their respective institutions and regulatory bodies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7"}}